Replies to post #383776 on Elite Pharmaceuticals Inc (ELTP)

[The ELTP King]

NOPE.

You didn't read the entire letter.

It's too late for them.

- "Based on DEA's internal analysis of inventory, manufacturing, and sales data submitted by manufacturers of amphetamine products, manufacturers only sold approximately 70 percent of their allotted quota for the year, and there were approximately 1 billion more doses that they could have produced but did not make or ship. Data for 2023 so far show a similar trend."

It might simply mean those not producing much actually start moving on it.

[The ELTP King]

$70 million in TOTAL revenue, not Adderall only.

2024 Additional Launches:
1. Vigabatrin (Scheduled to launch in 2023)
2. Dopamine Agonist
3. Antimetabolite
4. Dexcel Adderall
5. Generic OxyContin (2024 launch?)

Your $70M from Adderall is completely and entirely unreal for 2024.